Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Upregulated Vav2 signaling promotes regenerative proliferation in squamous cell carcinoma

ABSTRACT: Upregulated Vav2 signaling promotes regenerative proliferation in squamous cell carcinoma

PROVIDER: PRJNA510584 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Upregulated Vav2 signaling promotes regenerative proliferation in squamous cell carcinoma

Project description:Stem cell-like regenerative proliferation and undifferentiation cause poor prognosis in squamous cell carcinoma (SCC). Despite this, the signaling events driving to those traits remain ill-characterized. We report here that VAV2, an enzyme involved in RHO GTPase activation, becomes frequently upregulated in cutaneous and head-and-neck SCC, where it orchestrates a stem cell-like regenerative state.

2020-08-13 | GSE124019 | GEO

VAV2 signaling promotes regenerative proliferation in both cutaneous and head and neck squamous cell carcinoma.

Project description: Not available

| S-EPMC7508832 | biostudies-literature

Ruxolitinib inhibits Cyclosporine-induced proliferation of cutaneous squamous cell carcinoma

Project description:Ruxolitinib inhibits Cyclosporine-induced proliferation of cutaneous squamous cell carcinoma

| PRJNA481531 | ENA

EVI1 promotes proliferation and invasive properties of head and neck squamous cell carcinoma cells

Project description:EVI1 promotes proliferation and invasive properties of head and neck squamous cell carcinoma cells

| PRJNA777573 | ENA

EVI1 promotes proliferation and invasive properties of head and neck squamous cell carcinoma cells

Project description:Head and neck squamous cell carcinoma (HNSCC) is the tenth most common cancer worldwide. Alcohol and tobacco consumption are the predominant risk factors. Despite a multidisciplinary approach, the 5-year overall survival ranges only from 25% to 60%, depending on the site of origin. EVI1 expression increases with higher grading of HNSC tumors and over-expression was linked to a higher rate of lymph node metastasis. In lung cancer, its expression correlated negatively with patient survival. EVI1 was retrovirally over-expressed in CAL-33 and SCC-25 cells. Over-expression promoted proliferation, migration, and invasion of the cells. In CAL-33 cells, 1690 and 1684 genes were up- and down-regulated, respectively, at an FDR <0.1 in response to expression of EVI1. In SCC-25 cells, 334 significantly up- and 417 significantly down-regulated genes were identified. 71 and 181 genes were up- and down-regulated, respectively, in response to EVI1 expression in both cell lines. Gene ontology analysis revealed, among others, the terms epithelium development, extracellular matrix organisationorganization, cell adhesion, response to growth factor, and epithelial cell proliferation to be significantly enriched among the 252 genes that were regulated by EVI1 in a consistent manner in both cell lines.

2022-06-01 | GSE187454 | GEO

Ruxolitinib inhibits Cyclosporine-induced proliferation of cutaneous squamous cell carcinoma

Project description:Organ transplant recipients (OTRs) on Cyclosporine A (CSA) are prone to catastrophic cutaneous squamous cell carcinoma (SCC). Allograft-sparing, cancer-targeting systemic treatments are unavailable. We have shown increased risk for catastrophic SCC in OTRs via CSA-mediated induction of Interleukin-22 (IL-22). Herein, we found CSA drives SCC proliferation and tumor growth through IL-22 and JAK/STAT pathway induction. We in turn inhibited SCC growth with an FDA-approved JAK 1/2 inhibitor, Ruxolitinib. In human SCC cells, greatest proliferative response to IL-22 and CSA treatment occurred in non-metastasizing lines. IL-22 treatment upregulated JAK1 and STAT1/3 in A431 SCC cells. JAK/STAT pathway genes were highly expressed in tumors from a cohort of CSA-exposed OTRs, and in SCC with high risk for metastasis. Compared to immunocompetent SCC, genes associated with innate immunity, response to DNA damage and p53 regulation were differentially expressed in SCC from OTRs. In nude mice engrafted with human A431 cells, IL-22 and CSA treatment increased tumor growth and upregulated IL-22 receptor, JAK1 and STAT 1/3 expression. Ruxolitinib treatment significantly reduced tumor volume and reversed the accelerated tumor growth. CSA and IL-22 exacerbate aggressive behavior in SCC. Targeting the IL-22 axis via selective JAK/STAT inhibition may reduce the progression of aggressive SCC in OTRs, without compromising immunosuppression. In this study, microarray data was used to compare normal skin to immunocompetent SCC, to transplant associated SCC (TSCC)

2018-07-18 | GSE117247 | GEO

Quantitative proteomic profiling lung squamous carcinoma cells

Project description:Quantitative proteomic profiling the lung squamous carcinoma cells

2016-07-14 | MSV000079911 | MassIVE

CD271 is preferentially expressed and essential for cell proliferation in squamous cell carcinoma of the lung

Project description:Squamous cell carcinoma is a major type of cancer in the lung. While several therapeutic target molecules for lung adenocarcinoma have been identified, little is known about lung squamous cell carcinoma (LSCC). We recently reported that CD271 (p75 neurotrophin receptor) serves as a marker for tumor initiation and is a key regulator of cell proliferation in hypopharyngeal squamous cell carcinoma. In this study, we found that CD271 was also expressed in squamous cell carcinoma, but not in adenocarcinoma, of several tissues, including the lung. To examine CD271’s role in LSCC, we established xenograft cell lines from LSCC patients. Within the sorted live LSCC cell population, the CD271high cells were primarily cycling through the G2/M phase, while the CD271low cells were mostly in the G0 phase. CD271 knockdown in the LSCC cells completely suppressed their proliferation and tumor-formation capability, and increased their cell-cycle arrest in the G0 phase. In the CD271-knockdown cells, ERK-phosphorylation was decreased, while no change was observed in the IκBα-, p65-, or Akt-phosphorylation. Treatment with the MEK inhibitor U0126 decreased the LSCC cells’ proliferation capability. Microarray analysis revealed that CD271 knockdown attenuated the RAS-related pathways. The knockdown of TrkB, which forms a heterodimer with CD271 and accelerates its downstream signaling, partially inhibited the LSCC cell proliferation. These results indicated that LSCC exclusively depends on CD271 for cell proliferation, in part through ERK-signaling activation.

2021-08-06 | GSE118141 | GEO

Apolipoprotein E promotes invasion in oral squamous cell carcinoma

Project description:Genome-wide expression array measurements for 9 head and neck squamous cell carcinomas (HNSCC) stratified by worst pattern of invasion (WPOI) Jayakar et al. (2016). Apolipoprotein E promotes invasion in oral squamous cell carcinoma. Li et al. (2013). Validation of the risk model: high-risk classification and tumor pattern of invasion predict outcome for patients with low-stage oral cavity squamous cell carcinoma. Comparison of transcription profiles between OSCC tumors with a more invasive (WPOI 5) versus a less invasive (WPOI 3) pattern of invasion using two independent Illumina platforms.

2016-04-01 | E-GEOD-79795 | biostudies-arrayexpress

Circular RNA has_circ_0067934 is upregulated in esophageal squamous cell carcinoma and promoted proliferation.

Project description: Not available

| S-EPMC5067712 | biostudies-literature